Inhibition of adult T-cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Apr 2022
Historique:
revised: 27 12 2021
received: 06 08 2021
accepted: 19 01 2022
pubmed: 1 2 2022
medline: 12 4 2022
entrez: 31 1 2022
Statut: ppublish

Résumé

We have previously reported that the proanthocyanidin (PAC) fraction of blueberry leaf extract (BB-PAC) inhibits the proliferation of HTLV-1-infected adult T-cell leukemia (ATL) by inducing apoptosis. In the present study, we further analyzed the structure of BB-PAC and elucidated the molecular mechanism underlying the inhibitory function of HTLV-1-infected and ATL cells. After hot water extraction with fractionation with methanol-acetone, BB-PAC was found to be concentrated in fractions 4 to 7 (Fr7). The strongest inhibition of ATL cell growth was observed with Fr7, which contained the highest BB-PAC polymerization degree of 14. The basic structure of BB-PAC is mainly B-type bonds, with A-type bonds (7.1%) and cinchonain I units as the terminal unit (6.1%). The molecular mechanism of cytotoxicity observed around Fr7 against ATL cells was the degradation of JAK1 to 3 and the dephosphorylation of STAT3/5, which occurs by proteasome-dependent proteolysis, confirming that PAC directly binds to heat shock protein 90 (HSP90). JAK degradation was caused by proteasome-dependent proteolysis, and we identified the direct binding of PAC to HSP90. In addition, the binding of cochaperone ATPase homolog 1 (AHA1) to HSP90, which is required for activation of the cofactor HSP90, was inhibited by BB-PAC treatment. Therefore, BB-PAC inhibited the formation of the HSP90/AHA1 complex and promoted the degradation of JAK protein due to HSP90 dysfunction. These results suggest that the highly polymerized PAC component from blueberry leaves has great potential as a preventive and therapeutic agent against HTLV-1-infected and ATL cells.

Identifiants

pubmed: 35100463
doi: 10.1111/cas.15277
pmc: PMC8990289
doi:

Substances chimiques

HSP90 Heat-Shock Proteins 0
Proanthocyanidins 0
proanthocyanidin 18206-61-6
Proteasome Endopeptidase Complex EC 3.4.25.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1406-1416

Subventions

Organisme : the Shinnihon Foundation of Advanced Medical Treatment Research
Organisme : the Takeda Science Foundation
Organisme : the Japan Society for the Promotion of Science
ID : Grant-in-Aid for Scientific Research (B) 17H03581
Organisme : the Japan Society for the Promotion of Science
ID : Scientific Research (C) 18K07238
Organisme : the Japan Society for the Promotion of Science
ID : Scientific Research (C) 21K07128
Organisme : Shinnihon Foundation of Advanced Medical Treatment Research
Organisme : Takeda Science Foundation
Organisme : Japan Society for the Promotion of Science
ID : 17H03581
Organisme : Japan Society for the Promotion of Science
ID : 18K07238
Organisme : Japan Society for the Promotion of Science
ID : 21K07128

Informations de copyright

© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

J Biol Chem. 2009 Aug 7;284(32):21165-76
pubmed: 19531480
Sci Rep. 2015 Aug 13;5:12841
pubmed: 26269411
Nat Med. 2011 Jun 19;17(7):845-53
pubmed: 21685897
Science. 1995 Jul 7;269(5220):79-81
pubmed: 7604283
J Clin Invest. 1995 Sep;96(3):1548-55
pubmed: 7657825
Molecules. 2020 Dec 16;25(24):
pubmed: 33339407
Antivir Ther. 2009;14(4):533-42
pubmed: 19578238
Cell. 2006 Nov 17;127(4):803-15
pubmed: 17110338
Cancer Sci. 2021 Jan;112(1):22-30
pubmed: 33128318
Blood. 2011 Feb 10;117(6):1938-46
pubmed: 21106989
Biochim Biophys Acta Mol Basis Dis. 2019 Oct 1;1865(10):2633-2646
pubmed: 31295529
Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12480-5
pubmed: 26396258
J Clin Invest. 2010 Oct;120(10):3578-93
pubmed: 20852385
Cancer Sci. 2022 Apr;113(4):1406-1416
pubmed: 35100463
Nat Commun. 2014 Feb 26;5:3393
pubmed: 24569712
Biomed Pharmacother. 2019 Aug;116:108999
pubmed: 31146109
Toxicol Res. 2017 Oct;33(4):273-282
pubmed: 29071011
J Gen Virol. 1987 Feb;68 ( Pt 2):499-506
pubmed: 3029287
Cancer Res. 2008 Feb 15;68(4):1188-97
pubmed: 18281495
Biochem Biophys Res Commun. 2017 Mar 25;485(1):144-151
pubmed: 28189691
Biochim Biophys Acta Mol Cell Res. 2020 Feb;1867(2):118615
pubmed: 31765670
PLoS One. 2012;7(2):e31067
pubmed: 22348037
Nutr Cancer. 2014;66(4):736-46
pubmed: 24191894
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902
pubmed: 9391124
Food Chem Toxicol. 2017 Nov;109(Pt 1):534-543
pubmed: 28974439
PLoS One. 2015 May 27;10(5):e0128103
pubmed: 26018525
Signal Transduct Target Ther. 2021 Jan 20;6(1):25
pubmed: 33468990
Oncogenesis. 2017 Apr 3;6(4):e311
pubmed: 28368390
Biomed Res Int. 2018 Mar 12;2018:8584136
pubmed: 29750172
J Immunol. 2006 May 15;176(10):5797-804
pubmed: 16670285
Nat Rev Cancer. 2010 Aug;10(8):537-49
pubmed: 20651736
Cell Rep. 2015 Jun 9;11(9):1458-73
pubmed: 26027934
Carcinogenesis. 2008 Mar;29(3):585-93
pubmed: 17827407
Blood. 2015 Nov 26;126(22):2479-83
pubmed: 26443624
Clin Cancer Res. 2011 Dec 1;17(23):7347-58
pubmed: 21976548
Front Microbiol. 2020 May 29;11:1124
pubmed: 32547527

Auteurs

Tomonaga Ichikawa (T)

Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki, Japan.

Kazuhiro Sugamoto (K)

Department of Applied Chemistry, Faculty of Engineering, University of Miyazaki, Miyazaki, Japan.

Yasushi Matsuura (Y)

Miyazaki Prefectural Food Research and Development Center, Miyazaki, Japan.

Hisato Kunitake (H)

Department of Biochemistry and Applied Biosciences, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
Center for Collaborative Research and Community Cooperation, University of Miyazaki, Miyazaki, Japan.

Kazuya Shimoda (K)

Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Kazuhiro Morishita (K)

Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki, Japan.
Project for Advanced Medical Research and Development, Project Research Division, Frontier Science Research Center, University of Miyazaki, Miyazaki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH